Evidence map›Paper›PMID 41107444›Full record

ArticleScientific reports2025

The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery.

Haohao Lu, Bin Liang, Xiangwen Xia, Xuefeng Kan, Chuansheng Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haohao LuDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Bin LiangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Xiangwen XiaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Xuefeng KanDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. xkliulang1314@163.com.
Chuansheng ZhengDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. 1354039648@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective study evaluated the efficacy and safety of drug-eluting bead transarterial chemoembolization (D-TACE) combined with Donafenib and Tislelizumab versus D-TACE with Sorafenib in 105 patients with recurrent hepatocellular carcinoma (HCC) after surgical resection (January 2019-June 2023). Patients were divided into D-TACE + Donafenib + Tislelizumab (N = 51) and D-TACE + Sorafenib (N = 54) groups. The D-TACE + Donafenib + Tislelizumab group demonstrated significantly higher objective response rate (62.7% vs. 40.7%, P < 0.05) and disease control rate (84.3% vs. 64.8%, P < 0.05), along with prolonged median progression-free survival (8.7 vs. 5.7 months, P < 0.001) and overall survival (19.2 vs. 12.3 months, P < 0.001). While hypothyroidism incidence was higher in the D-TACE + Donafenib + Tislelizumab group (21.6% vs. 7.4%, P = 0.051), the D-TACE + Sorafenib group exhibited increased fatigue (35.2% vs. 11.8%, P = 0.006) and anorexia (35.2% vs. 13.7%, P = 0.013). These findings suggest that D-TACE combined with Donafenib and Tislelizumab offers superior tumor control and survival benefits with a manageable safety profile, representing a promising therapeutic strategy for postoperative recurrent HCC.

Indexed as

Antibodies, Monoclonal, HumanizedCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsNeoplasm Recurrence, LocalPyridinesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedRetrospective StudiesSorafenibTreatment OutcomeAntibodies, Monoclonal, HumanizedPyridinesSorafenibtislelizumabHepatocellular carcinomaImmune checkpoint inhibitorsImmunotherapyInterventional therapyPostoperative recurrenceTargeted therapyTransarterial chemoembolization (TACE)

Identifiers

PMID41107444
PMCPMC12534493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.